南京医药
(600713)
| 流通市值：57.58亿 | | | 总市值：72.01亿 |
| 流通股本：10.47亿 | | | 总股本：13.09亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 40,938,180,822.52 | 27,232,110,530.43 | 13,952,545,044.79 | 53,589,664,728.2 |
| 营业收入 | 40,938,180,822.52 | 27,232,110,530.43 | 13,952,545,044.79 | 53,589,664,728.2 |
| 二、营业总成本 | 40,123,096,334.31 | 26,666,946,892.11 | 13,662,722,944.53 | 52,645,439,177.52 |
| 营业成本 | 38,414,540,220.25 | 25,552,871,035.22 | 13,111,847,569.11 | 50,276,361,667.87 |
| 税金及附加 | 85,321,921.41 | 54,788,761.23 | 25,446,447.28 | 107,592,787.25 |
| 销售费用 | 845,968,276.41 | 557,873,681.7 | 281,364,661.06 | 1,173,100,689.57 |
| 管理费用 | 346,175,353.89 | 209,416,358.44 | 101,959,459.26 | 517,443,394.34 |
| 研发费用 | 30,536,340.65 | 22,290,489.93 | 10,233,235.61 | 36,189,149.34 |
| 财务费用 | 400,554,221.7 | 269,706,565.59 | 131,871,572.21 | 534,751,489.15 |
| 其中:利息费用 | 266,514,175.23 | 170,525,181.31 | 88,832,297.87 | 378,493,807.68 |
| 其中:利息收入 | 10,172,311.34 | 6,395,645.21 | 3,976,161.57 | 10,135,446.88 |
| 加:投资收益 | 3,096,723.62 | 1,038,058.45 | 105,359.12 | 8,581,039.56 |
| 资产处置收益 | 4,301,998.51 | 4,037,344.55 | 4,292,232.17 | 2,197,111.2 |
| 资产减值损失(新) | -2,124,236.1 | -4,920,761.62 | -467,143.06 | -6,248,448.65 |
| 信用减值损失(新) | -68,814,673.14 | -33,852,885.36 | -36,263,872.43 | 19,292,413.03 |
| 其他收益 | 20,063,924.66 | 14,061,127.87 | 6,053,263.55 | 39,395,059.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 771,608,225.76 | 545,526,522.21 | 263,541,939.61 | 1,007,442,725.13 |
| 加:营业外收入 | 8,418,950.45 | 7,915,006.84 | 3,620,443.28 | 2,566,390.75 |
| 减:营业外支出 | 17,472,745.23 | 12,558,709.97 | 4,947,198.37 | 31,941,001.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 762,554,430.98 | 540,882,819.08 | 262,215,184.52 | 978,068,113.93 |
| 减:所得税费用 | 198,747,894 | 143,338,410.13 | 65,268,064.78 | 265,259,209.01 |
| 六、净利润 | 563,806,536.98 | 397,544,408.95 | 196,947,119.74 | 712,808,904.92 |
| 持续经营净利润 | 563,806,536.98 | 397,544,408.95 | 196,947,119.74 | 712,808,904.92 |
| 归属于母公司股东的净利润 | 441,882,390.22 | 311,321,223.12 | 159,082,706.83 | 577,825,648.39 |
| 少数股东损益 | 121,924,146.76 | 86,223,185.83 | 37,864,412.91 | 134,983,256.53 |
| (一)基本每股收益 | 0.34 | 0.24 | 0.12 | 0.45 |
| (二)稀释每股收益 | 0.34 | 0.24 | 0.12 | 0.45 |
| 八、其他综合收益 | 28,155,158.32 | -7,698,594.37 | -6,229,608.08 | 7,536,148.64 |
| 归属于母公司股东的其他综合收益 | 27,157,780.85 | -8,110,084.78 | -5,948,477 | 7,748,553.76 |
| 九、综合收益总额 | 591,961,695.3 | 389,845,814.58 | 190,717,511.66 | 720,345,053.56 |
| 归属于母公司股东的综合收益总额 | 469,040,171.07 | 303,211,138.34 | 153,134,229.83 | 585,574,202.15 |
| 归属于少数股东的综合收益总额 | 122,921,524.23 | 86,634,676.24 | 37,583,281.83 | 134,770,851.41 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-08 |
| 审计意见(境内) | | | | 标准无保留意见 |